These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 25206276)

  • 21. Current and future targets and therapies in metastatic colorectal cancer.
    Dzunic M; Petkovic I; Cvetanovic A; Vrbic S; Pejcic I
    J BUON; 2019; 24(5):1785-1792. PubMed ID: 31786838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication.
    Moradi Marjaneh R; Khazaei M; Ferns GA; Avan A; Aghaee-Bakhtiari SH
    IUBMB Life; 2019 Oct; 71(10):1428-1441. PubMed ID: 31322820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.
    Ballestrero A; Garuti A; Cirmena G; Rocco I; Palermo C; Nencioni A; Scabini S; Zoppoli G; Parodi S; Patrone F
    Curr Cancer Drug Targets; 2012 May; 12(4):316-28. PubMed ID: 22385512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How to select the optimal treatment for first line metastatic colorectal cancer.
    Stein A; Bokemeyer C
    World J Gastroenterol; 2014 Jan; 20(4):899-907. PubMed ID: 24574764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of miRNAs in colorectal cancer progression and chemoradiotherapy.
    Zhang N; Hu X; Du Y; Du J
    Biomed Pharmacother; 2021 Feb; 134():111099. PubMed ID: 33338745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular targets for colon cancer. VEGF, EGFR - and what else?].
    Röcken C
    Pathologe; 2008 Nov; 29 Suppl 2():200-3. PubMed ID: 18810446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNAs as Therapeutic Targets and Colorectal Cancer Therapeutics.
    Yamamoto H; Mori M
    Adv Exp Med Biol; 2016; 937():239-47. PubMed ID: 27573904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-coding RNAs Enabling Prognostic Stratification and Prediction of Therapeutic Response in Colorectal Cancer Patients.
    Perakis SO; Thomas JE; Pichler M
    Adv Exp Med Biol; 2016; 937():183-204. PubMed ID: 27573901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.
    Mlcochova J; Faltejskova-Vychytilova P; Ferracin M; Zagatti B; Radova L; Svoboda M; Nemecek R; John S; Kiss I; Vyzula R; Negrini M; Slaby O
    Oncotarget; 2015 Nov; 6(36):38695-704. PubMed ID: 26497852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of microRNAs in 5-FU resistance of colorectal cancer: Possible mechanisms.
    Marjaneh RM; Khazaei M; Ferns GA; Avan A; Aghaee-Bakhtiari SH
    J Cell Physiol; 2019 Mar; 234(3):2306-2316. PubMed ID: 30191973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNAs as novel biomarkers for colorectal cancer: New outlooks.
    Shirafkan N; Mansoori B; Mohammadi A; Shomali N; Ghasbi M; Baradaran B
    Biomed Pharmacother; 2018 Jan; 97():1319-1330. PubMed ID: 29156521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.
    Fanale D; Castiglia M; Bazan V; Russo A
    Adv Exp Med Biol; 2016; 937():207-28. PubMed ID: 27573902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies.
    de Mello RA; Marques AM; Araújo A
    World J Gastroenterol; 2013 Oct; 19(38):6315-8. PubMed ID: 24151349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and advancing treatments for metastatic colorectal cancer.
    Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
    Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNAs and Apoptosis in Colorectal Cancer.
    Wang H
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32731413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.